Related Experiment Video

Updated: May 21, 2026

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis
06:17

A11-positive β-amyloid Oligomer Preparation and Assessment Using Dot Blotting Analysis

Published on: May 22, 2018

Pleiotropic protective effects of phytochemicals in Alzheimer's disease

Sergio Davinelli1, Nadia Sapere, Davide Zella

  • 1Clinical Biochemistry and Clinical Molecular Biology Laboratory, Department of Health Sciences, University of Molise, 86100 Campobasso, Italy.

Oxidative Medicine and Cellular Longevity
|June 13, 2012
PubMed

Insights

Phytochemicals like curcumin, catechins, and resveratrol show neuroprotective potential against Alzheimer's disease (AD). These compounds offer antioxidant, anti-inflammatory, and antiamyloidogenic benefits, suggesting new therapeutic avenues for AD.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Biochemistry

Background:

  • Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting memory and cognition.
  • Current understanding of AD pathogenesis is incomplete, with limited therapeutic options available.
  • The heterogeneity of AD necessitates treatments targeting multiple pathological pathways.

Purpose of the Study:

  • To explore the neuroprotective potential of specific phytochemicals against Alzheimer's disease.
  • To discuss the role of polyphenols, including curcumin, catechins, and resveratrol, in AD therapy.
  • To highlight the molecular targets and therapeutic value of these compounds in AD.

Main Methods:

  • Review of scientific literature on phytochemicals and Alzheimer's disease.
  • Analysis of antioxidant, anti-inflammatory, and antiamyloidogenic mechanisms of selected polyphenols.
  • Focus on molecular targets and neuroprotective functions of curcumin, catechins, and resveratrol.

Main Results:

  • Phytochemicals, particularly polyphenols, exhibit significant neuroprotective properties.
  • Curcumin, catechins, and resveratrol demonstrate antioxidant, anti-inflammatory, and antiamyloidogenic activities.
  • These compounds interact with specific molecular targets relevant to AD pathology.

Conclusions:

  • Phytochemicals represent a promising resource for developing novel drug candidates for Alzheimer's disease.
  • Targeting multiple pathways with compounds like curcumin, catechins, and resveratrol may offer a more effective therapeutic strategy for AD.
  • Further research into the molecular mechanisms of these phytochemicals could unlock their full therapeutic potential in AD treatment.

More Related Videos

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells12:55

Assay for Phosphorylation and Microtubule Binding Along with Localization of Tau Protein in Colorectal Cancer Cells

Published on: October 10, 2017

Related Concept Videos

Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...